BA
ALXN

BlackRock Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$214M Sell
1,751,063
-535,828
-23% -$65.6M 0.22% 111
2016
Q3 		$280M Buy
2,286,891
+1,295,520
+131% +$167M 0.29% 86
2016
Q2 		$116M Sell
991,371
-27,413
-3% -$3.89M 0.12% 187
2016
Q1 		$142M Sell
1,018,784
-302,034
-23% -$44.3M 0.15% 156
2015
Q4 		$252M Sell
1,320,818
-182,608
-12% -$31.9M 0.27% 93
2015
Q3 		$235M Buy
1,503,426
+157,434
+12% +$28.7M 0.25% 100
2015
Q2 		$243M Buy
1,345,992
+181,251
+16% +$31.3M 0.25% 106
2015
Q1 		$202M Sell
1,164,741
-100,701
-8% -$18.2M 0.21% 123
2014
Q4 		$234M Sell
1,265,442
-89,970
-7% -$16.7M 0.24% 113
2014
Q3 		$225M Sell
1,355,412
-49,437
-4% -$8.12M 0.22% 113
2014
Q2 		$220M Buy
1,404,849
+238,442
+20% +$37.6M 0.21% 121
2014
Q1 		$177M Buy
1,166,407
+535,161
+85% +$85.1M 0.17% 144
2013
Q4 		$83.9M Buy
631,246
+234,371
+59% +$28.1M 0.08% 254
2013
Q3 		$46.1M Sell
396,875
-811,517
-67% -$89M 0.05% 341
2013
Q2 		$111M Buy
+1,208,392
New +$116M 0.12% 190

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock Advisors's ALXN Position: Q4 2016 in Review

BlackRock Advisors reduced its Alexion Pharmaceuticals (ALXN) stake by 23% in Q4 2016, selling an estimated $65.6M and leaving 1,751,063 shares worth $214M. The position accounts for 0.22% of the portfolio, ranked #111.

BlackRock Advisors first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $280M in Q3 2016. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • BlackRock Advisors held 1,751,063 shares of Alexion Pharmaceuticals worth $214M as of Q4 2016.
  • BlackRock Advisors sold 535,828 Alexion Pharmaceuticals shares in Q4 2016, an estimated $65.6M.
  • Alexion Pharmaceuticals made up 0.22% of BlackRock Advisors's portfolio in Q4 2016, its #111 holding.
  • BlackRock Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Alexion Pharmaceuticals position peaked at $280M in Q3 2016.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.